Overview

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Open-label, randomized multicenter phase III non-inferiority study
Phase:
Phase 3
Details
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Treatments:
Azacitidine